English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Therapeutic strategies based on optimization of the unique human LL37 cathelecin sequences including FK16, the core active sequence of LL37, have already been proposed. In this study we have characterized TatIV13 a new host defense hybrid peptide, that combined YGRRKKRRQRRR, the hydrophobic N-terminalfragment of HIV-1 Tat47-57 cell penetrating sequence, with IV13, a short IVQRIKDFLRNLV inactivesequence resulting from the deletion of the three N-terminal amino acid residues of FK16. Tat- IV13displayed potent host defense inhibitory effects leading both to the survival inhibition of U87G cells, aglioblastoma model, and to the inhibition of the growth of S. agalactiae NEM316 ΔdltA strain, a Gram+bacterial model. These results suggest that identification of hybrid specific Tat-cathelecidin peptides withhigh anti-tumor activity and anti-bactericidal activity may represent a powerful approach to identify newcandidates for future therapeutic developments.

clinical microbiology and research

Anti-Microbial and Anti-Cancer Properties of Tat-IV13, A Hybrid Bi-Partite Peptide Containing The Short Non Active Iv13 Sequence of Human Ll37 Cathelecidin